The breast cancer chemoprevention debate.
Charlie
C
Schmidt
D000077384:Anastrozole; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000517:prevention & control*; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015233:Models, Statistical; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects
D000730:Androstadienes; D016588:Anticarcinogenic Agents; D047072:Aromatase Inhibitors; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D020849:Raloxifene Hydrochloride; C056516:exemestane